Summary
We have evaluated the results of salvage systemic therapy in 257 patients with breast cancer recurrent after surgical adjuvant treatment with cyclophosphamide, fluorouracil, and prednisone (CFP) with or without tamoxifen. The overall objective response rate to salvage hormonal therapy was 29% (47 responses in 161 patients) and to salvage chemotherapy was 28% (43 responses in 156 patients). Response rates to salvage chemotherapy were similar whether or not prior salvage hormonal therapy or local modalities had been administered. Retreatment with CFP as a salvage chemotherapy yielded responses in 11 of 44 patients (25%). Response rates were similar for patients who began salvage CFP ≤12 months or >12 months after completion of adjuvant CFP. We conclude that when this unselected population of patients failing adjuvant CFP is considered, 1) response rates to salvage chemotherapy were low regardless of whether or not prior salvage hormonal or local therapies were given, 2) repeating adjuvant chemotherapy (CFP) following relapse produced a low response rate, and 3) response rates to salvage hormonal therapy were low, but on the order of those observed in patients with advanced disease unselected by estrogen receptor status who are treated with first line hormonal maneuvers.
This is a preview of subscription content, log in via an institution to check access.
References
Buzdar AU, Legha SS, Hortobagyi GN, Yap HY, Wiseman CL, Distefano A, Schell FC, Barnes BC, Campos LT, Blumenschein GR: Management of breast cancer patients failing adjuvant chemotherapy with Adriamycin-containing regimens. Cancer 47: 2798–2806, 1981
Valagussa P, Tancini G, Bonadonna G: Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 58: 1411–1417, 1986
Bonadonna G, Valagussa P, Rossi A, Tancini G, Brambella C, Zambetti M, Veronesi U: Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5: 95–115, 1985
Wendt AG, Jones SE, Salmon SE: Salvage treatment of patients relapsing after breast cancer adjuvant chemotherapy. Cancer Treat Rep 64: 269–273, 1980
Morris DM, Elias EG, Didolkar MS, Brown SD: The response to further chemotherapy in patients with carcinoma of the breast who progressed while receiving adjuvant therapy. J Surg Oncol 29: 154–157, 1985
Ahmann DL, Scanlon PW, Bisel HF, Edmonson JH, Frytak S, Payne WS, O'Fallon JR, Hahn RG, Ingle JN, O'Connell MJ, Rubin J: Repeated adjuvant chemotherapy with phenylalanine mustard or 5-fluorouracil, cyclophosphamide, and prednisone with or without radiation, after mastectomy for breast cancer. Lancet i: 893–896, 1978
Ahmann DL, O'Fallon JR, Scanlon PW, Payne WS, Bisel HF, Edmonson JH, Frytak S, Hahn RG, Ingle JN, Rubin J, Creagan ET: A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy. Am J Clin Oncol (CCT) 5: 371–381, 1982
Everson LK, Ingle JN, Wieand HS, Martin JK, Votava HJ, Fitzgibbons RG, Weiland LH, Krook JE, Ahmann DL, Cullinan SA: Randomized trial of adjuvant therapy with cyclophosphamide, 5-fluorouracil, prednisone, with or without tamoxifen following mastectomy in premenopausal women with node positive breast cancer. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Proc Am Soc Clin Oncol 5: 63, 1986
Ingle JN, Everson LK, Wieand HS, Martin JK, Votava HJ, Wold LE, Krook JE, Cullinan SA, Paulsen JK, Twito DI, Ahmann KL, Foley JF, Green SJ: Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer. J Clin Oncol 6: 1388–1396, 1988
Legha SS, Blumenschein GR: Systemic therapy of metastatic breast cancer: a review of the current trends. Oncology 39: 140, 1982
Bonadonna G, Valagussa P: Chemotherapy of breast cancer: current views and results. Int J Radiat Oncol Biol Phys 9: 279–297, 1983.
Author information
Authors and Affiliations
Additional information
Additional participating institutions: 1) Allan Blain Memorial Clinic, Regina, Saskatchewan, Canada (M.A. Poon), 2) Billings Clinic, Billings, MT (D.I. Twito),3) Creighton University, Omaha, NE (J.A. Mailliard),4) Grand Forks Clinic, Grand Forks, ND (J.Laurie), 5) Iowa Oncology Research Association CCOP, Des Moines, IA (R.F. Morton),6) St. Cloud Clinic of Internal Medicine, St. Cloud, MN (H.E. Windschitl), 7) Sioux Falls Community Cancer Consortium CCOP, Sioux Falls, SD (R.F. Marschke), 8) University of Nebraska Medical Center, Omaha, NE (J.F. Foley).
Address for offprints: North Central Cancer Treatment Group, Operations Office, 200 First Street S.W., Rochester, MN 55905, USA.
Rights and permissions
About this article
Cite this article
Buckner, J.C., Ingle, J.N., Everson, L.K. et al. Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer. Breast Cancer Res Tr 13, 135–142 (1989). https://doi.org/10.1007/BF01806525
Issue Date:
DOI: https://doi.org/10.1007/BF01806525